In lung cancer, presence of PSMA is mainly observed on the neovasculature (Table 1), with expression levels in primary tumors ranging from 45% (63/141 patients) in adenocarcinoma to 70% in large cell carcinoma (49/70) and SCLC (21/30) [104, 105]. The gene discussed is FOLH1; the disease is small cell lung carcinoma.